Ardent Health outlines $40M annual benefit from impact program as cost headwinds persist
View original at seekingalpha.comArdent Health outlines $40M annual benefit from impact program as cost headwinds persist Earnings Call Insights: Ardent Health, Inc…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Cost pressures are not demand-driven; revenue guidance remains unchanged but earnings pull-through has been impacted
80% confidenceYear-to-date adjusted EBITDA is up 30% with margin improvements
80% confidenceThe $43M revenue reduction from Kodiak RCA is a change in accounting estimate, representing difference in reserve timing between the two models
80% confidence100% of the $54M malpractice charge relates to New Mexico market experiencing significant social inflationary pressure in medical malpractice cases
80% confidenceCompany is ramping up litigation efforts and demand letters to address payer denials
80% confidenceThere is strong durable demand going into 2026
80% confidenceStrong platform and initiatives drove admissions growth of 5.8% in Q3
80% confidenceQ3 revenue increased 8.8% to $1.58 billion driven by adjusted admissions growth of 2.9% and net patient service revenue per adjusted admission growth of 5.8%
80% confidencePayer denials are fairly uniform across all categories including managed care, Medicare, Medicaid, and health exchanges
80% confidenceCompany terminated a payer contract, payer came back to negotiate better rates and terms to prevent denial activity
80% confidenceYear-to-date through Q3, adjusted EBITDA grew 30% and margins expanded 150 basis points to 8.7%
80% confidenceUpdated outlook prudently assumes industry headwinds observed in Q3 will persist at elevated levels in Q4
80% confidenceQ3 adjusted EBITDA increased 46% to $143 million with margin increasing by 240 basis points to 9.1%
80% confidenceMargin enhancement and efficiency initiatives will provide annual benefit of more than $40 million at full run rate in early 2026
80% confidenceIt would be premature to discuss share repurchases, but Board will look at every option to optimize shareholder value over time
80% confidenceEarnings performance in Q3 did not meet expectations
80% confidence